Paclitaxel is an effective antiproliferative agent on the human NCI-H295 adrenocortical carcinoma cell line

Chemotherapy
Francesco FalloN Sonino

Abstract

In view of a potential clinical use, we assessed the antiproliferative effect of paclitaxel on the human steroid-secreting NCI-H295 adrenocarcinoma cell line. By MTT, paclitaxel induced a dose-dependent inhibition of cell proliferation, with IC50 lower than blood levels of the drug achieved in patients treated for other malignancies. Cell exposure to paclitaxel for 24 h at the different IC50S produced a dose-responsive increase in DNA fragmentation, morphologically confirmed by electron microscopy. A time-dependent decrease in aldosterone, cortisol and testosterone was observed. Paclitaxel is an effective antiproliferative agent in this human adrenocortical carcinoma cell line. Apoptosis induced by the drug in involved in neoplastic cell death. A potential role of the drug in the treatment of patients with adrenocortical cancer could be considered.

Citations

Sep 27, 2001·World Journal of Surgery·A P DackiwD B Evans
Dec 16, 2011·Hormones & Cancer·Michael J DemeureLawrence S Kirschner
Mar 25, 2000·Endocrinology and Metabolism Clinics of North America·C A Stratakis, G P Chrousos
Jan 8, 2011·The Oncologist·Lyndal J TaconStan B Sidhu
Feb 18, 2014·Endocrine-related Cancer·Constanze HantelFelix Beuschlein
Feb 25, 2015·International Journal of Oncology·Lidia CerquettiAntonio Stigliano
Sep 20, 2011·Molecular and Cellular Endocrinology·Tao Wang, William E Rainey
Feb 21, 2004·Biochemical and Biophysical Research Communications·Eunyoung Chun, Ki-Young Lee
Jun 28, 2001·Current Problems in Surgery·J A NortonH N Le

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior. Here are the latest discoveries pertaining to this disease.

© 2022 Meta ULC. All rights reserved